[1] WORLD HEALTH ORGANIZATION. Global tuberculosis report2025[EB/OL]. [2025-11-12]. https://iris.who.int/handle/10665/383364. [2] JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS. Global HIV & AIDS statistics — fact sheet2025[EB/OL]. [2025-07-13]. https://www.unaids.org/en/resources/fact-sheet. [3] WORLD HEALTH ORGANIZATION.The End TB Strategy[EB/OL]. [2015-08-16]. https://iris.who.int/handle/10665/331326. [4] WORLD HEALTH ORGANIZATION.Tuberculosis among populations at high risk and people in vulnerable situations: policy brief[EB/OL]. [2025-07-10]. https://www.who.int/publications/i/item/B09350. [5] UNITED NATIONS GENERAL ASSEMBLY. Political declaration of the high-level meeting on the fight against tuberculosis [EB/OL]. [2023-10-05]. https://digitallibrary.un.org/record/4025280?ln=zh_CN&v=pdf. [6] WORLD HEALTH ORGANIZATION.Consolidated guidance on tuberculosis data generation and use: module 1: tuberculosis surveillance[EB/OL]. [2024-04-19]. https://iris.who.int/handle/10665/376612. [7] WORLD HEALTH ORGANIZATION. INTERNATIONAL LABOUR ORGANIZATION.Guidance on social protection for people affected by tuberculosis[EB/OL]. [2025-05-20]. https://iris.who.int/handle/10665/376542. [8] WORLD HEALTH ORGANIZATION. Multisectoral accountability framework to accelerate progress to end tuberculosis by2030[EB/OL]. [2019-12-31]. https://iris.who.int/handle/10665/331934. [9] LITVINJENKO S, MAGWOOD O, WU S, et al.Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews[J]. Lancet Infect Dis. 2023;23(12): 1395-1407. [10] WORLD HEALTH ORGANIZATION.WHO consolidated guidelines on tuberculosis: module 2: screening-systematic screening for tuberculosis disease[EB/OL]. [2021-02-22]. https://iris.who.int/handle/10665/340255. [11] 黄嘉敏, 柯学, 李国保, 卢水华. 《WHO结核病整合指南模块1:预防——结核病预防性治疗(第二版)》解读[J/CD]. 新发传染病电子杂志, 2025, 10(3): 92-98. [12] MARTINEZ L, CORDS O, HORSBURGH CR, et al.The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis[J]. Lancet. 2020, 395(10228): 973-984. [13] BARRETO-DUARTE B, VILLALVA-SERRA K, MIGUEZ-PINTO JP, et al.Interplay between biological & social vulnerability and poor tuberculosis treatment outcome in Brazil: a nationwide study using multivariate modelling with excess risk[J]. Lancet Reg Health Am, 2025, 53: 101305. [14] WORLD HEALTH ORGANIZATION.WHO consolidated guidelines on tuberculosis: module 4: treatment and care[EB/OL]. [2025-03-14]. https://iris.who.int/handle/10665/380799. [15] World Health Organization.World report on social determinants of health equity[EB/OL]. [2025-05-06]. https://iris.who.int/handle/10665/381152. [16] DONKIN A, GOLDBLATT P, ALLEN J, et al.Global action on the social determinants of health[J]. BMJ Glob Health, 2017, 3: e000603. [17] SIROKA A, PONCE NA, LÖNNROTH K. Association between spending on social protection and tuberculosis burden: a global analysis[J]. Lancet Infect Dis, 2016, 16(4): 473-479. [18] 王歆尧, 姜美丽, 庞元捷, 等. 中国结核病疾病负担现状[J]. 中华流行病学杂志, 2024, 45(6): 857-864. [19] LÖNNROTH K, CASTRO KG, CHAKAYA JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development[J]. Lancet, 2010, 375(9728): 1814-1829. [20] 姜游力, 张培泽, 邓国防, 等. 结核病患者诊断延迟及其影响因素研究进展[J]. 结核与肺部疾病杂志, 2021, 2(03): 289-293. [21] TEO AKJ, SINGH SR, PREM K, et al.Duration and determinants of delayed tuberculosis diagnosis and treatment in high-burden countries: a mixed-methods systematic review and meta-analysis[J]. Respir Res, 2021, 22(1): 251. [22] 李涛, 赵飞, 周林, 等. 结核病脆弱人群识别与精准干预策略研究进展[J/CD]. 新发传染病电子杂志, 2024, 9(4): 289-296. [23] 王美霁, 李锋. 脂阿拉伯甘露聚糖抗原检测用于艾滋病病毒感染者和艾滋病患者结核病诊断的研究进展[J]. 中华结核和呼吸杂志, 2024, 47(5): 475-480. [24] 杨芳, 黄琼, 张云桂. HIV感染者开展结核病预防性治疗的研究进展[J]. 实用预防医学, 2025, 32(2):253-256. [25] SWINDELLS S, RAMCHANDANI R, GUPTA A, et al.One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis[J]. N Engl J Med, 2019, 380(11): 1001-1011. [26] STERLING TR, VILLARINO ME, BORISOV AS, et al.Three months of rifapentine and isoniazid for latent tuberculosis infection[J]. N Engl J Med, 2011, 365(23): 2155-2166. [27] SARANJAV A, PARISI C, ZHOU X, et al.Assessing the quality of tuberculosis care using routine surveillance data: a process evaluation employing the Zero TB Indicator Framework in Mongolia[J]. BMJ Open, 2022, 12(8): e061229. [28] CLARK RA, MCQUAID CF, RICHARDS AS, et al.The potential impact of reductions in international donor funding on tuberculosis in low-income and middle-income countries: a modelling study[J]. Lancet Glob Health, 2025, 13(9): e1517-e1524. [29] 徐彩红, 张文宏, 赵雁林. 开展基于社区和机构的主动筛查提升结核病患者发现水平[J]. 中华传染病杂志, 2025, 43(3): 129-134. [30] 陈伟, 李雪, 刘小秋, 等. 《全国结核病防治规划(2024-2030年)》解读[J]. 中国防痨杂志, 2025, 47(2): 130-136. [31] 刘巧, 李忠奇, 竺丽梅, 等. 中国结核病防治服务体系运行现状、问题与对策研究[J]. 中国防痨杂志, 2025, 47(5): 559-568. [32] 中华人民共和国国家卫生健康委员会. 国家卫生健康委员会2022年4月25日新闻发布会文字实录:党的十八大以来我国职业健康工作进展与成效[EB/OL]. [2022-04-25]. https://www.nhc.gov.cn/xcs/c100122/202204/8a9cf8191a654f59ab799bfb07427566.shtml. [33] SCHWAB TC, PERRIG L, GÖLLER PC, et al. Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2024, 24(10): 1162-1176. [34] 国家疾病预防控制局, 等. 全国结核病防治规划(2024—2030年) [J/CD]. 新发传染病电子杂志,2025, 10(1): 94-96. [35] VYNNYCKY E.Lifetime risks, incubation period, and serial interval of tuberculosis[J]. Am J Epidemiol. 2000;152(3): 247-263. |